Alexandre Prat

List of Publications by Citations

178 papers	14,124 citations	62 h-index	116 g-index
196 ext. papers	17,581 ext. citations	11.3 avg, IF	6.57 L-index

#	Paper	IF	Citations
178	The blood-brain barrier. *Cold Spring Harbor Perspectives in Biology*, **2015**, 7, a020412	10.2	1245
177	Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. *Nature Medicine*, **2007**, 13, 1173-5	50.5	1178
176	Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. *Nature Medicine*, **2016**, 22, 586-97	50.5	629
175	The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. *Science*, **2011**, 334, 1727-31	33.3	513
174	Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. *Annals of Neurology*, **2009**, 66, 390-402	9.4	390
173	Glial influence on the blood brain barrier. *Glia*, **2013**, 61, 1939-58	9	318
172	Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. *Nature Immunology*, **2008**, 9, 137-45	19.1	309
171	Brain-immune connection: Immuno-regulatory properties of CNS-resident cells. *Glia*, **2000**, 29, 293-304	9	289
170	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. *Nature Medicine*, **2014**, 20, 1147-56	50.5	267
169	Glial cell influence on the human blood-brain barrier. *Glia*, **2001**, 36, 145-55	9	254
168	An updated histological classification system for multiple sclerosis lesions. *Acta Neuropathologica*, **2017**, 133, 13-24	14.3	253
167	Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. *Science Translational Medicine*, **2015**, 7, 310ra166	17.5	242
166	How do immune cells overcome the blood-brain barrier in multiple sclerosis?. *FEBS Letters*, **2011**, 585, 3770-80	3.8	232
165	Disruption of central nervous system barriers in multiple sclerosis. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 252-64	6.9	212
164	Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. *Journal of Immunology*, **2008**, 181, 5730-7	5.3	200
163	How do immune cells support and shape the brain in health, disease, and aging?. *Journal of Neuroscience*, **2013**, 33, 17587-96	6.6	198
162	Immunologic privilege in the central nervous system and the blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 13-21	7.3	188

161	Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. *Journal of Neuroscience*, **2007**, 27, 9032-42	6.6	178
160	Defining secondary progressive multiple sclerosis. *Brain*, **2016**, 139, 2395-405	11.2	172
159	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA - Journal of the American Medical Association*, **2019**, 321, 175-187	27.4	172
158	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. *Nature Neuroscience*, **2019**, 22, 729-740	25.5	166
157	Treatment optimization in MS: Canadian MS Working Group updated recommendations. *Canadian Journal of Neurological Sciences*, **2013**, 40, 307-23	1	159
156	Determinants of human B cell migration across brain endothelial cells. *Journal of Immunology*, **2003**, 170, 4497-505	5.3	155
155	The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. *Brain*, **2008**, 131, 785-99	11.2	141
154	Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. *Journal of Immunology*, **2014**, 193, 2438-54	5.3	140
153	Retinoic acid induces blood-brain barrier development. *Journal of Neuroscience*, **2013**, 33, 1660-71	6.6	139
152	Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. *Cell*, **2019**, 176, 610-624.e18	36.2	133
151	Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. *Annals of Neurology*, **2006**, 60, 45-55	9.4	127
150	Peroxisome proliferator-activated receptor (PPAR)-and -regulate IFN-and IL-17A production by human T cells in a sex-specific way. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 9505-10	11.5	125
149	MAFG-driven astrocytes promote CNS inflammation. *Nature*, **2020**, 578, 593-599	50.4	125
148	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Annals of Neurology*, **2016**, 80, 89-100	9.4	117
147	Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. *Immunity*, **2015**, 43, 1160-73	32.3	117
146	Pathogenesis of multiple sclerosis. *Current Opinion in Neurology*, **2005**, 18, 225-30	7.1	115
145	Defining reliable disability outcomes in multiple sclerosis. *Brain*, **2015**, 138, 3287-98	11.2	107
144	MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: implications for multiple sclerosis. *Journal of Neuroscience*, **2013**, 33, 6857-63	6.6	107

143	Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. *Annals of Neurology*, **2013**, 73, 341-54	9.4	105
142	Netrin 1 regulates blood-brain barrier function and neuroinflammation. *Brain*, **2015**, 138, 1598-612	11.2	103
141	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. *Lancet Neurology, The*, **2017**, 16, 271-281	24.1	101
140	Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. *Annals of Neurology*, **2011**, 70, 751-63	9.4	99
139	Migration of multiple sclerosis lymphocytes through brain endothelium. *Archives of Neurology*, **2002**, 59, 391-7		99
138	Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. *Brain*, **2012**, 135, 2906-24	11.2	97
137	Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. *Nature Medicine*, **2009**, 15, 788-93	50.5	93
136	Myeloid cell transmigration across the CNS vasculature triggers IL-1-driven neuroinflammation during autoimmune encephalomyelitis in mice. *Journal of Experimental Medicine*, **2016**, 213, 929-49	16.6	93
135	Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on 4 integrin. *Brain*, **2011**, 134, 3560-77	11.2	92
134	Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. *Neurobiology of Disease*, **2015**, 74, 14-24	7.5	87
133	Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. *PLoS ONE*, **2012**, 7, e40443	3.7	87
132	Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. *Glia*, **2012**, 60, 1145-59	9	87
131	Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. *Journal of Biological Chemistry*, **2008**, 283, 27220-9	5.4	87
130	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. *Frontiers in Immunology*, **2015**, 6, 636	8.4	82
129	Glial influences on BBB functions and molecular players in immune cell trafficking. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 472-82	6.9	81
128	Interferon- secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon- therapy. *Annals of Neurology*, **1999**, 45, 247-250	9.4	78
127	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurology, The*, **2020**, 19, 307-316	24.1	77
126	NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. *Journal of Neuroscience*, **2007**, 27, 1220-8	6.6	77

125	Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. *Archives of Neurology*, **2005**, 62, 563-8		76
124	Environmental Control of Astrocyte Pathogenic Activities in CNS Inflammation. *Cell*, **2019**, 176, 581-596.e18	36.2	74
123	Interpericyte tunnelling nanotubes regulate neurovascular coupling. *Nature*, **2020**, 585, 91-95	50.4	73
122	Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. *Journal of Neuropathology and Experimental Neurology*, **2003**, 62, 412-9	3.1	69
121	Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 1127-36	3.1	68
120	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. *JAMA Neurology*, **2013**, 70, 1315-24	17.2	67
119	A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected]. *PLoS ONE*, **2014**, 9, e105421	3.7	65
118	Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. *Journal of Neuroimmunology*, **2000**, 108, 201-6	3.5	63
117	Gut-licensed IFN□NK cells drive LAMP1TRAIL anti-inflammatory astrocytes. *Nature*, **2021**, 590, 473-479	50.4	63
116	IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation. *Brain*, **2016**, 139, 1939-57	11.2	62
115	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *Brain*, **2017**, 140, 2426-2443	11.2	62
114	Kinin B1 receptor expression and function on human brain endothelial cells. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 896-906	3.1	61
113	Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis. *Journal of Immunology*, **2013**, 190, 2510-8	5.3	60
112	Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. *Cell*, **2019**, 179, 1483-1498.e22	56.2	59
111	Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?. *Trends in Neurosciences*, **2016**, 39, 325-339	13.3	58
110	Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. *Frontiers in Immunology*, **2015**, 6, 626	8.4	57
109	Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. *Pharmaceutical Research*, **2007**, 24, 1262-74	4.5	55
108	Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E524-E533	11.5	53

107	Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity. *Frontiers in Immunology*, **2015**, 6, 657	8.4	52
106	USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation. *Nature Immunology*, **2017**, 18, 54-63	19.1	51
105	IL-1 enables CNS access to CCR2 monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E1194-E1203	11.5	49
104	Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. *Annals of Neurology*, **1999**, 46, 253-6	9.4	48
103	B7 expression and antigen presentation by human brain endothelial cells: requirement for proinflammatory cytokines. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 129-36	3.1	47
102	B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. *Journal of Immunology*, **2011**, 187, 4119-28	5.3	46
101	Functions of lipid raft membrane microdomains at the blood-brain barrier. *Journal of Molecular Medicine*, **2009**, 87, 765-74	5.5	46
100	Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation. *Annals of Neurology*, **2015**, 78, 39-53	9.4	43
99	Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. *Multiple Sclerosis Journal*, **2017**, 23, 72-81	5	41
98	Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. *Journal of Neuroinflammation*, **2011**, 8, 155	10.1	40
97	ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 2894-2909	7.3	39
96	Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat. *British Journal of Pharmacology*, **1992**, 107, 750-5	8.6	38
95	Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses. *Glia*, **2016**, 64, 553-69	9	38
94	Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. *Journal of Autoimmunity*, **2005**, 24, 119-24	15.5	37
93	Targeting the GM-CSF receptor for the treatment of CNS autoimmunity. *Journal of Autoimmunity*, **2017**, 84, 1-11	15.5	35
92	An optimized method to process mouse CNS to simultaneously analyze neural cells and leukocytes by flow cytometry. *Journal of Neuroscience Methods*, **2015**, 247, 23-31	3	34
91	Extracellular matrix metalloproteinase inducer shows active perivascular cuffs in multiple sclerosis. *Brain*, **2013**, 136, 1760-77	11.2	33
90	Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. *ELife*, **2019**, 8,	8.9	33

89	Glial regulation of the blood-brain barrier in health and disease. *Seminars in Immunopathology*, **2015**, 37, 577-90	12	32
88	MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. *Brain*, **2019**, 142, 2979-2995	11.2	32
87	Death receptor expression and function at the human blood brain barrier. *Journal of the Neurological Sciences*, **2007**, 259, 53-60	3.2	32
86	T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. *Journal of Neuroimmunology*, **2001**, 115, 161-7	3.5	32
85	Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. *Glia*, **2003**, 42, 36-45	9	31
84	Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2-polarized lymphocytes. *Journal of Neuropathology and Experimental Neurology*, **2004**, 63, 223-32	3.1	31
83	Barcoded viral tracing of single-cell interactions in central nervous system inflammation. *Science*, **2021**, 372,	33.3	29
82	Blood-brain barrier promotes differentiation of human fetal neural precursor cells. *Stem Cells*, **2009**, 27, 838-46	5.8	28
81	Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. *Journal of Neuroinflammation*, **2018**, 15, 114	10.1	27
80	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. *Science Translational Medicine*, **2019**, 11,	17.5	27
79	Th1 polarization of CD4+ T cells by Toll-like receptor 3-activated human microglia. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 848-59	3.1	27
78	Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. *Archives of Neurology*, **2005**, 62, 795-800		27
77	Risk of secondary progressive multiple sclerosis: A longitudinal study. *Multiple Sclerosis Journal*, **2020**, 26, 79-90	5	27
76	JAML mediates monocyte and CD8 T cell migration across the brain endothelium. *Annals of Clinical and Translational Neurology*, **2015**, 2, 1032-7	5.3	26
75	Characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation. *Canadian Journal of Physiology and Pharmacology*, **1995**, 73, 892-902	2.4	26
74	Update on treatments in multiple sclerosis. *Presse Medicale*, **2015**, 44, e137-51	2.2	25
73	Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. *Canadian Journal of Neurological Sciences*, **2018**, 45, 489-503	1	25
72	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon □*Multiple Sclerosis Journal*, **2014**, 20, 1783-7	5	25

71	CD70 defines a subset of proinflammatory and CNS-pathogenic T1/T17 lymphocytes and is overexpressed in multiple sclerosis. *Cellular and Molecular Immunology*, **2019**, 16, 652-665	15.4	24
70	Contribution of different relapse phenotypes to disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 266-276	5	22
69	Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. *Journal of Immunology*, **2017**, 198, 3245-3254	5.3	22
68	Inflammation-induced endothelial to mesenchymal transition promotes brain endothelial cell dysfunction and occurs during multiple sclerosis pathophysiology. *Cell Death and Disease*, **2019**, 10, 45	9.8	22
67	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. *Multiple Sclerosis and Related Disorders*, **2019**, 28, 235-243	4	22
66	EGFL7 reduces CNS inflammation in mouse. *Nature Communications*, **2018**, 9, 819	17.4	21
65	Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 1617-1626	5	21
64	Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: Relation to magnetic resonance imaging lesion volume. *Annals of Neurology*, **2000**, 47, 234-237	9.4	21
63	Comparative efficacy of first-line natalizumab vs IFN- or glatiramer acetate in relapsing MS. *Neurology: Clinical Practice*, **2016**, 6, 102-115	1.7	21
62	Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. *Nature Neuroscience*, **2021**, 24, 489-503	25.5	21
61	One more role for the gut: microbiota and blood brain barrier. *Annals of Translational Medicine*, **2016**, 4, 15	3.2	20
60	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. *Multiple Sclerosis Journal*, **2018**, 24, 642-652	5	18
59	Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. *Clinical Immunology*, **2004**, 111, 38-46	9	18
58	NG2 immunoreactivity on human brain endothelial cells. *Acta Neuropathologica*, **2001**, 102, 313-20	14.3	18
57	Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis. *Scientific Reports*, **2018**, 8, 13437	4.9	18
56	Overcoming the Brain Barriers: From Immune Cells to Nanoparticles. *Trends in Pharmacological Sciences*, **2020**, 41, 42-54	13.2	15
55	EphrinB1 and EphrinB2 regulate T cell chemotaxis and migration in experimental autoimmune encephalomyelitis and multiple sclerosis. *Neurobiology of Disease*, **2016**, 91, 292-306	7.5	15
54	Humanized mouse model of Rasmussen encephalitis supports the immune-mediated hypothesis. *Journal of Clinical Investigation*, **2018**, 128, 2000-2009	15.9	14

53	Isolation of human brain endothelial cells and characterization of lipid raft-associated proteins by mass spectroscopy. *Methods in Molecular Biology*, **2011**, 686, 275-95	1.4	14
52	Glial Cells as Regulators of Neuroimmune Interactions in the Central Nervous System. *Journal of Immunology*, **2020**, 204, 251-255	5.3	14
51	Laquinimod enhances central nervous system barrier functions. *Neurobiology of Disease*, **2017**, 102, 60-69	7.5	13
50	Early clinical markers of aggressive multiple sclerosis. *Brain*, **2020**, 143, 1400-1413	11.2	13
49	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. *JAMA Neurology*, **2018**, 75, 1407-1415	17.2	13
48	Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization. *British Journal of Pharmacology*, **1994**, 112, 250-6	8.6	13
47	A roadmap to precision medicine for multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 522-532	5	12
46	Brain-immune connection: Immuno-regulatory properties of CNS-resident cells **2000**, 29, 293		11
45	Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption. *Journal of Neuroimmunology*, **2018**, 319, 9-12	3.5	10
44	Human brain endothelial cells supply support for monocyte immunoregulatory functions. *Journal of Neuroimmunology*, **2003**, 135, 96-106	3.5	9
43	IVIVC Assessment of Two Mouse Brain Endothelial Cell Models for Drug Screening. *Pharmaceutics*, **2019**, 11,	6.4	9
42	Isolation of endothelial cells, pericytes and astrocytes from mouse brain. *PLoS ONE*, **2019**, 14, e0226302	3.7	9
41	Frailty in ageing persons with multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 613-620	5	9
40	Notch signaling is impaired during inflammation in a Lunatic Fringe-dependent manner. *Brain, Behavior, and Immunity*, **2018**, 69, 48-56	16.6	8
39	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. *Science Advances*, **2021**, 7, eabj5629	14.3	8
38	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. *JAMA Neurology*, **2020**, 77, 1398-1407	17.2	8
37	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. *Brain*, **2020**, 143, 2742-2756	11.2	8
36	Antigen and superantigen presentation in the human CNS. *Journal of Neuroimmunology*, **2000**, 107, 118-23	3.5	7

35	Interleukin-26, preferentially produced by T17 lymphocytes, regulates CNS barrier function. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	7
34	RNA-binding protein altered expression and mislocalization in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	7
33	IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8. *Theranostics*, **2021**, 11, 1-13	12.1	7
32	Anaesthetic doses of pentobarbital antagonize phosphatidylinositol hydrolysis induced by substance P or carbachol in the spinal cord and cerebral cortex of the rat. *European Journal of Pharmacology*, **1992**, 227, 103-7		6
31	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. *Journal of Clinical Investigation*, **2021**, 131,	15.9	6
30	Endo-MitoEGFP mice: a novel transgenic mouse with fluorescently marked mitochondria in microvascular endothelial cells. *PLoS ONE*, **2013**, 8, e74603	3.7	5
29	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality		5
28	Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. *Acta Neuropathologica*, **2021**, 141, 725-754	14.3	5
27	From Balo concentric sclerosis to multiple sclerosis: a series of 6 patients. *Multiple Sclerosis and Related Disorders*, **2020**, 42, 102078	4	4
26	Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases. *Nature Reviews Neurology*, **2021**, 17, 433-447	15	4
25	Multiple sclerosis-associated uveitis. *Expert Review of Ophthalmology*, **2017**, 12, 57-67	1.5	3
24	Assessing the risk of multiple sclerosis disease-modifying therapies. *Expert Review of Neurotherapeutics*, **2019**, 19, 695-706	4.3	3
23	Sex-dependent factors encoded in the immune compartment dictate relapsing or progressive phenotype in demyelinating disease. *JCI Insight*, **2019**, 4,	9.9	3
22	DICAM promotes T17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation.. *Science Translational Medicine*, **2022**, 14, eabj0473	17.5	3
21	QUAKING Regulates Microexon Alternative Splicing of the Rho GTPase Pathway and Controls Microglia Homeostasis. *Cell Reports*, **2020**, 33, 108560	10.6	3
20	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 755-766	5	3
19	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. *Multiple Sclerosis and Related Disorders*, **2021**, 53, 103012	4	3
18	Ephrin B1 and B2 are essential for the pathogenicity and migration capacity of TH17 cells in EAE and MS. *Journal of Neuroimmunology*, **2014**, 275, 140	3.5	2

17	Special issue on molecular basis of multiple sclerosis. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 131	6.9	2
16	Neuropeptide K potently stimulates the hydrolysis of phosphatidylinositol in the rat spinal cord. *Neuroscience Letters*, **1993**, 159, 95-8	3.3	2
15	Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis.. *Journal of Neuroinflammation*, **2022**, 19, 27	10.1	2
14	Author response: Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry **2019**,		2
13	Oxidative Modifications of Parkin Underlie its Selective Neuroprotection in Adult Human Brain		2
12	Determinants of therapeutic lag in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 1838-1851	5	2
11	Interferon-β secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-β therapy **1999**, 45, 247		2
10	Characterization of the cardiovascular and behavioral effects of centrally administered neuropeptide K in the conscious rat. *Regulatory Peptides*, **1993**, 46, 317-20		1
9	Productivity loss among people with early multiple sclerosis: A Canadian study.. *Multiple Sclerosis Journal*, **2022**, 13524585211069070	5	1
8	Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant. *Current Oncology*, **2020**, 28, 203-208	2.8	1
7	Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry		1
6	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. *CNS Drugs*, **2021**, 35, 1217-1232	6.7	1
5	Roles of CD4 and CD8 T Lymphocytes in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis **2015**, 39-52		0
4	The IL-27/IL-27R axis is altered in CD4 and CD8 T lymphocytes from multiple sclerosis patients. *Clinical and Translational Immunology*, **2021**, 10, e1262	6.8	0
3	CCR6 Expression on B Cells Is Not Required for Clinical or Pathological Presentation of MOG Protein-Induced Experimental Autoimmune Encephalomyelitis despite an Altered Germinal Center Response. *Journal of Immunology*, **2021**, 207, 1513-1521	5.3	0
2	Inflammation at the Blood–Brain Barrier in Multiple Sclerosis. *Topics in Medicinal Chemistry*, **2013**, 117-142	0.4	
1	Blood-Brain Barrier Disruption in Multiple Sclerosis **2015**, 1-22		